1) Walsh SLF, Lederer DJ, Ryerson CJ, et al:Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 200:1146-1153, 2019
2) Kondoh Y, Taniguchi H, Kataoka K, et al:Disease severity staging system for idiopathic pulmonary fibrosis in Japan. Respirology 22:1609-1614, 2017
3) Morisset J, Johannson KA, Jones KD, et al:Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis. An International Modified Delphi Survey. Am J Respir Crit Care Med 197:1036-1044, 2018
4) Raghu G, Remy-Jardin M, Ryerson CJ, et al:Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 202:e36-e69, 2020
5) Maher TM, Corte TJ, Fischer A, et al:Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease:a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med 8:147-157, 2020
6) George PM, Spagnolo P, Kreuter M, et al:Progressive fibrosing interstitial lung disease:clinical uncertainties, consensus recommendations, and research priorities. Lancet Respir Med 8:925-934, 2020
7) Walsh SLF, Calandriello L, Silva M, et al:Deep learning for classifying fibrotic lung disease on high-resolution computed tomography:a case-cohort study. Lancet Respir Med 6:837-845, 2018
